Pfizer initiated a Phase 1b trial for PF-07304814 in September. The study will evaluate the safety, tolerability and pharmacokinetics of PF-07304814 in patients with SARS-CoV-2 virus infection and with mild-to-moderate symptoms, PF-07304814 is a phosphate prodrug that when administered intravenously is metabolized to the active compound PF-00835321, which is shown to be a very potent inhibitor of the SARS-CoV-2 coronavirus (or COVID-19) in pre-clinical studies. The study is double-blind and placebo-controlled, meaning approximately half of the participants will receive the study medicine intravenously and the other half will receive a placebo (an injection with no active ingredient) and neither participants nor investigators know who is getting which. If the study is successful, we anticipate starting a Phase 2/3 trial to better understand the safety and efficacy of the compound in a larger patient population.